1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Align Technology said C. Raymond Larkin, Jr. will retire as Chairman of the Board effective July 1, 2026, and Kevin Conroy, an independent director, will succeed him as Chairman on the same date. Mr. Larkin will remain a director until December 31, 2026, and the filing says his decision to leave the Board is not due to any disagreement with the company and that he was not removed for cause.
Larkin notified the Board on June 17, 2026 and will step down as Chairman effective July 1, 2026.
Larkin will stay on the Board, including the Nominating and Governance Committee, through December 31, 2026.
Conroy has been an independent director since December 2023 and chairs the Compensation and Human Capital Committee since January 2026.
Conroy was Chairman and CEO of Exact Sciences until Abbott Laboratories acquired it in March 2026.
Mueller Water Products said its Senior Vice President and Chief Human Resources Officer, Todd P. Helms, will leave the company effective September 1, 2026. He will serve as a senior advisor under a consulting agreement through September 30, 2026, to ensure an orderly transition.
Todd P. Helms, SVP and Chief Human Resources Officer, departs effective September 1, 2026
Consulting agreement runs until September 30, 2026, with a consulting fee of $5,000
Helms will receive severance under the Executive Severance Plan, filed as Exhibit 10.39 to the 10-K filed November 19, 2025
Atmos Energy completed a public offering of $700 million aggregate principal amount of 4.750% senior notes maturing January 15, 2032, on June 18, 2026. The company said it received net proceeds of approximately $693.9 million after the underwriting discount and estimated offering expenses, and the notes are unsecured and rank equally with its other unsubordinated debt.
Principal amount: $700 million of 4.750% senior notes due January 15, 2032
Estimated net proceeds: approximately $693.9 million after underwriting discount and offering expenses
Interest payable January 15 and July 15 each year, beginning January 15, 2027
Indenture covenants limit specified liens, sale-leaseback transactions, mergers and the sale of substantially all assets
At its June 16, 2026 annual meeting, Match Group stockholders did not approve, on an advisory basis, the pay of the named executive officers for fiscal 2025, with more votes against than in favor. Stockholders also approved an amendment to the 2024 stock and incentive plan, adding 6,250,000 shares, and elected four directors, so shareholders should note the rejected pay vote as a signal of concern about executive compensation.
Say-on-pay proposal not approved: 85,252,504 votes for, 114,012,022 against, 93,135 abstaining.
Second Amended and Restated 2024 Stock and Annual Incentive Plan approved: 133,116,903 for, 66,173,398 against; adds 6,250,000 shares and extends the term to the tenth anniversary of the 2026 annual meeting.
Ann L. McDaniel received 34,663,099 votes against, the largest opposition among the four director nominees, all of whom were elected to one-year terms.
Stockholders ratified Ernst & Young LLP as independent registered accounting firm for fiscal 2026 with 199,786,113 votes in favor.
Actinium Pharmaceuticals submitted a compliance plan to NYSE American on June 18, 2026, describing actions management intends to take to restore compliance with listing standards. The exchange had notified the company on May 27, 2026 that its stockholders' equity was below the $4.0 million minimum required under Section 1003(a)(ii) of the NYSE American Company Guide, which applies after losses in three of four recent fiscal years.
June 18, 2026: Company submitted its compliance plan to NYSE American.
May 27, 2026: Company received the NYSE American notice regarding stockholders' equity.
Required minimum: stockholders' equity of $4.0 million or more under Section 1003(a)(ii).
The filing does not specify the individual actions management plans to take.
Yorkville International Capital Corp. (YICC) closed its initial public offering on June 17, 2026, selling 23,000,000 units at $10.00 each, including 3,000,000 units from the underwriter's full over-allotment option. The company is a blank check company that has not selected a business combination target, and the $230 million raised is held in a trust account until a business combination is completed or shareholders redeem their shares within 24 months of the IPO closing.
Closed June 17, 2026: 23,000,000 units at $10.00 each, for gross proceeds of $230 million before underwriting discounts and offering expenses
$230 million placed in a U.S.-based trust account with Continental Stock Transfer & Trust Company as trustee, including up to $9.2 million of deferred underwriting discount and commissions
Private placement of 6,300,000 warrants at $1.00 each: 4,000,000 to the sponsor and 2,300,000 to Cohen & Company Capital Markets
Trust funds are not released until a business combination, redemption of public shares if no business combination is completed within 24 months, or a shareholder vote to change those terms
Fidelity National Information Services said its Chief Legal & Corporate Affairs Officer and Corporate Secretary, Caroline Tsai, will step down effective July 1, 2026, and will serve as a non-executive senior advisor until September 1, 2026 to help with the transition. Chip Keller, currently Chief Compliance Officer and Corporate Secretary, will take over as Chief Legal Officer and Corporate Secretary on the same date.
Caroline Tsai's departure is effective July 1, 2026; she is expected to serve as a senior advisor until September 1, 2026.
Chip Keller will become Chief Legal Officer and Corporate Secretary effective July 1, 2026.
Tsai will receive severance and other benefits under her employment agreement, as described in the April 28, 2026 proxy statement.
Honest Company entered a 10-year lease dated June 14, 2026 for about 38,240 rentable square feet in Playa Vista, California, and plans to move its headquarters there by May 1, 2027. The filing puts expected net base rent over the initial term at approximately $33.4 million and requires a $1.2 million letter of credit, which are the main financial commitments for shareholders to note.
Lease with Dellwood Farm LLC covers about 38,240 rentable square feet at 12121 Bluff Creek Drive, Suite 500, Playa Vista, California.
Lease term starts on the later of March 1, 2027 or substantial completion of tenant improvements, and runs 10 years.
Expected total base rent, net of a ten-month abatement, is approximately $33,440,756; landlord provides a $180.00 per square foot tenant improvement allowance.
Company must provide an irrevocable $1.2 million letter of credit; current headquarters lease expires April 30, 2027.
GRI Bio said on June 18, 2026 that the U.S. Food and Drug Administration granted Orphan Drug Designation to GRI-0621, its oral investigational therapy for idiopathic pulmonary fibrosis (IPF). The designation provides potential benefits such as seven years of U.S. market exclusivity upon approval, but the filing does not report revenue, earnings, or changes to guidance.
FDA granted Orphan Drug Designation to GRI-0621 for IPF, announced June 18, 2026
Orphan designation applies to diseases affecting fewer than 200,000 people in the U.S.; benefits include potential seven years of U.S. market exclusivity upon approval
GRI-0621 was evaluated in a 35-patient Phase 2a trial (GRI-0621-IPF-02), which the company says met its primary, secondary and exploratory endpoints
Centrus Energy stockholders approved a seventh amendment to the company's Section 382 rights agreement at the June 18, 2026 annual meeting. The amendment extends the plan's final expiration date to June 30, 2029 and raises the purchase price per preferred share fraction, which the company says reflects the rise in its Class A common stock price. The company says the plan is intended to preserve its net operating loss carryforwards and other tax benefits for stockholders, and that it was not adopted in response to any effort to acquire control.
Final Expiration Date extended from June 30, 2026 to June 30, 2029.
Purchase price per one one-thousandth of a Series A preferred share increased from $160.38 to $1,143.95.
Stockholders approved the amendment on June 18, 2026 with 7,664,845 votes for and 853,077 against.
Yanhong Dai appointed principal accounting officer effective June 18, 2026, with a $250,000 base salary; Todd M. Tinelli remains CFO.
Momentus has a sales agreement with A.G.P./Alliance Global Partners that lets it sell up to $75 million of Class A common stock over time, at its option, through the agent. The shares would be issued under a Form S-3 shelf that the SEC declared effective on June 4, 2026, and a prospectus supplement filed June 18, 2026, so the sales could dilute existing shareholders.
Maximum aggregate amount: up to $75 million of Class A common stock, sold at the company's option
Agent: A.G.P./Alliance Global Partners, acting as sales agent
Registration: Form S-3 (File No. 333-296218) filed May 26, 2026, declared effective June 4, 2026
Legal opinion from Bradley Arant Boult Cummings LLP filed as Exhibit 5.1
Mondelēz International said Amit Banati will become Executive Vice President and Chief Financial Officer on July 1, 2026, reporting to Chair and CEO Dirk Van de Put. Banati most recently served as CFO of Kenvue, Inc. from May 2025 to May 2026, and earlier as CFO of Kellanova and Kellogg. Luca Zaramella, who the company said served as CFO for eight years, will continue as Executive Vice President and Chief Operating Officer.
Start date: July 1, 2026; Banati will be a member of the Mondelēz International Leadership Team
Base salary of $1,050,000 with a 125% target annual incentive and a $5,000,000 target annual long-term equity grant for 2026
Make-whole cash award of up to $7,000,000 for compensation Banati must forfeit at his former employer, subject to repayment on certain termination events before the second anniversary of the start date
Luca Zaramella remains Executive Vice President and Chief Operating Officer
Tyson Foods entered into a Third Amended and Restated Employment Agreement with Chairman John H. Tyson on June 17, 2026, replacing his 2017 agreement. The filing sets a base salary of $3,500,000, a one-time incentive cash payment of $40,000,000, and a term ending September 30, 2029, with severance and security perks, which shareholders may view as a significant compensation commitment.
Initial term ends September 30, 2029, with automatic three-year renewals unless terminated.
Annual base salary of $3,500,000; annual incentive target of 300% of base salary; long-term incentive target grant value of $6,000,000.
One-time incentive award cash payment of $40,000,000, partly subject to pro-rata repayment if he resigns without Good Reason or is terminated for Cause before September 30, 2029.
Termination without Cause or for Good Reason triggers a lump sum payment, the greater of two years of target pay or the remaining term's pay, plus security services and life insurance premium reimbursement.
NextDecade's indirect subsidiary RGLNG HoldCo Borrower signed a $1.0 billion term loan credit agreement on June 17, 2026, with Wilmington Trust, National Association, as administrative and collateral agent. The company said the proceeds will mainly fund an equity contribution to Rio Grande LNG, LLC, which will use it to reduce its credit facility borrowings. The new debt sits at the holding-company level, is secured by the borrower's assets, and carries covenants shareholders may want to track.
$1.0 billion term loan matures June 17, 2033, with interest at 7.05% per year.
Proceeds mainly fund an equity contribution to RGLNG to reduce its credit facility borrowings, plus fees, expenses and general and administrative costs.
Interest is paid in kind until the first interest payment date after the third anniversary of the closing date, unless the borrower elects cash payment.
Covenants include a debt service coverage ratio of at least 1.05:1.00 each fiscal quarter, and mandatory prepayment at 101% upon a change of control.
Sonoma Pharmaceuticals filed a prospectus supplement increasing the aggregate offering price under its at-the-market share sales agreement with Ladenburg Thalmann to $3,641,703. Since September 26, 2025, the company has sold 173,073 shares for $574,633, so the larger amount gives it room to raise more equity from the program, which could dilute existing shareholders.
Shares sold under the agreement from September 26, 2025 through the filing date: 173,073 shares for $574,633
Aggregate offering price raised to $3,641,703 via a supplement filed June 18, 2026
Shares previously registered but not yet sold total $1,495,830
Cantor Equity Partners VII, Inc. closed its initial public offering of 25,000,000 Class A ordinary shares at $10.00 per share on June 18, 2026, generating $250,000,000 in gross proceeds. The full $250,000,000 from the IPO and a concurrent private placement was placed in a trust account, and the company must complete an initial business combination within 24 months of the IPO closing or redeem the public shares, which matters to shareholders because their capital is held pending that deal.
25,000,000 Class A ordinary shares sold at $10.00 each, for gross proceeds of $250,000,000; shares trade on Nasdaq as CAES, beginning June 17, 2026.
$250,000,000 placed in a trust account at J.P. Morgan Chase Bank, N.A., maintained by Continental Stock Transfer & Trust Company, as trustee.
Sponsor Cantor EP Holdings VII, LLC bought 600,000 private placement Class A shares at $10.00 each, for $6,000,000.
The underwriters did not exercise the over-allotment option; 937,500 Class B shares surrendered by the sponsor were cancelled.
Construction Partners amended its Term Loan B credit agreement on June 18, 2026, refinancing existing term loans and adding $300.0 million in incremental term loans. The aggregate term loan principal rose from $839.4 million to $1,139.4 million, with maturity set for November 1, 2031.
Aggregate term loan principal increased from $839.4 million to $1,139.4 million
Incremental term loans of $300.0 million, plus refinancing of all outstanding term loans to reduce interest rate margins
Pricing steps down 0.25% per annum if consolidated first lien net leverage is below 2.95-to-1.00, tested first on September 30, 2026
Share repurchases under a new basket capped at $50.0 million per fiscal year, subject to conditions
Hamilton Beach Brands disclosed that Andrew C. Carington left his posts as Senior Vice President, General Counsel and Secretary, and as an employee of the company and its affiliates, effective immediately on June 18, 2026. The filing does not give a reason for the departure or name a successor.
Departing officer: Andrew C. Carington, Senior Vice President, General Counsel and Secretary
Effective date: June 18, 2026, with immediate effect
The filing does not name a replacement or state the reason for the departure
Epsilon Energy entered a Sales Agreement with Roth Capital Partners on June 18, 2026, allowing it to sell up to $15,000,000 of common shares over time through at-the-market offerings. The company is not obligated to sell any shares, and sales will occur at prevailing market prices, so the program may dilute existing shareholders if used.
Maximum aggregate offering price of up to $15,000,000 in common shares, no par value
Roth Capital Partners receives a 3.0% commission on gross proceeds from any shares sold
Shares issued under a Form S-3 shelf registration filed January 13, 2026 and effective January 22, 2026
BrightView Holdings amended its credit agreement, extending the maturity of its seven-year term loans to June 17, 2033, and amended its receivables financing agreement, extending its scheduled termination date to June 12, 2029. The company said the extensions strengthen balance sheet flexibility and provide additional runway for its strategic priorities. The filing does not report revenue, earnings, or guidance changes.
Term loan maturity extended from April 2029 to June 17, 2033, under Amendment No. 11 to the Credit Agreement dated June 17, 2026
Receivables facility scheduled termination date extended to June 12, 2029, under the Sixth Amendment dated June 12, 2026
Agreements were with JPMorgan Chase Bank, N.A. (credit agreement) and PNC Bank, National Association (receivables facility)
Whirlpool Finance Luxembourg entered into a First Supplemental Indenture on June 18, 2026, amending the indenture for its 1.100% Notes due 2027 to change the satisfaction and discharge period from one year to two years. The amendment follows a tender offer and consent solicitation, with holders of approximately 91.12% of the 2027 Notes validly tendering, enough to approve the change. The amendment becomes operative once Whirlpool purchases all tendered notes at the offer's expiration.
Tenders as of June 12, 2026 totaled €546,715,000 of the 2027 Notes, about 91.12% of outstanding principal, which the filing says was sufficient for the requisite consents.
The amendment replaces "one year" with "two years" in Section 10.01, accelerating the issuer's ability to satisfy and discharge the indenture for the 2027 Notes.
The amendment takes effect once the company purchases all tendered 2027 Notes at the expiration of the Tender Offer and Consent Solicitation, described in a statement dated June 1, 2026.
The supplemental indenture is filed as Exhibit 4.1 with trustee U.S. Bank Trust Company, National Association.
AmperCap Acquisition Company completed its initial public offering of 12,500,000 units at $10.00 each on June 4, 2026, for gross proceeds of $125 million. On June 10, 2026, underwriters partly exercised their over-allotment option, buying 1,837,500 more units for $18.375 million; the company says the remaining 37,500 option units will not be issued. The filing reports two different trust account amounts, $144,808,750 in one section and $126.25 million on the June 4 balance sheet, so the amount held for shareholders is not clear from this document.
IPO of 12,500,000 units at $10.00 per unit, closed June 4, 2026, for gross proceeds of $125,000,000
Private placement of 512,500 units for $5,125,000, plus 55,125 more private units for $551,250 after the over-allotment closed
Partial over-allotment exercise on June 10, 2026 for 1,837,500 units, generating $18,375,000
Trust account figures conflict: $144,808,750 cited in the text versus $126,250,000 on the June 4 balance sheet
PTC Therapeutics completed a private offering of $550 million in 0.0% convertible senior notes due June 15, 2031, including the full $50 million option exercised by the initial purchasers. The company is using about $328.8 million of the estimated $535.5 million net proceeds to repurchase $222.0 million of its existing 1.50% convertible notes due 2026, leaving $55.5 million of those notes outstanding, which shifts its debt toward the new notes for shareholders.
Notes: $550 million principal, 0.0% interest, maturing June 15, 2031
Initial conversion price of approximately $107.48 per share (9.3042 shares per $1,000 principal)
Estimated net proceeds of $535.5 million; $328.8 million used to repurchase $222.0 million of 2026 notes
Existing 1.50% convertible notes outstanding after repurchases: $55.5 million
On June 17, 2026, Viatris completed a public offering of €650 million of 4.250% senior unsecured notes due June 17, 2033. The company plans to use the proceeds mainly to repay revolving credit facility borrowings tied to the June 2026 maturity of $1.675 billion of 3.950% notes, with any remainder used to replenish cash. For shareholders, the filing shows the company refinancing a maturing debt obligation with new long-term debt.
Offering size: €650 million aggregate principal amount of 4.250% senior notes due June 17, 2033
Interest is payable annually starting June 17, 2027; notes are guaranteed by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc.
Proceeds intended first to repay revolver borrowings tied to the repayment of the entire $1.675 billion 3.950% notes due 2026
If a change of control event occurs, Viatris must offer to buy the notes at 101% of principal plus accrued interest
On June 18, 2026, the CEO, CFO and COO of M3-Brigade Acquisition V Corp. resigned, along with three directors, and the board named Chinh Chu, the company's President, as principal executive officer and Thomas Boychuk as CFO. The filing states that none of the resignations resulted from a disagreement with the company, and that neither appointee will receive compensation for the new role. The filing names M3-Brigade Acquisition V Corp., not Velos Acquisition I Corp. as the ticker VLOS suggests, so the registrant's identity should be confirmed.
Robert Rivas Collins resigned as CEO and Eric Greenhaus resigned as CFO, principal financial officer and principal accounting officer, both effective June 18, 2026
Matthew Perkal resigned as Chief Operating Officer and from the board, along with directors Mohsin Y. Meghji and Benjamin Fader-Rattner
Chinh Chu, President since May 2025 and a CC Capital founder, was appointed principal executive officer; Thomas Boychuk, 44, was appointed CFO
Neither Chu nor Boychuk will receive compensation for the new roles, and both are affiliated with the sponsor's parent CC Capital
CoreWeave completed a private offering of $1,250 million of 9.625% senior notes and €2,000 million of 8.500% senior notes, both maturing July 15, 2032. The company says it will use the proceeds for general corporate purposes, including repaying existing indebtedness, and to pay offering costs. The notes add to CoreWeave's debt obligations, and their terms include restrictive covenants limiting additional debt, dividends and asset sales.
USD Notes: $1,250 million at 9.625%, maturing July 15, 2032
EUR Notes: €2,000 million at 8.500%, maturing July 15, 2032
Interest paid semi-annually in cash, beginning January 15, 2027; interest accrues from June 18, 2026
Notes are senior unsecured, guaranteed by certain CoreWeave subsidiaries; optional redemption before July 15, 2029 includes a make-whole premium
Kopin sold its equity in Lightning Silicon Technology and LS Assets to those companies for $1.00 each on June 10, 2026, and the shares were retired, leaving Kopin with no equity interest in either. Kopin also confirmed that its technology license with LST ended April 10, 2026, and set transition and royalty terms, which the company says are not expected to have a material effect on its consolidated financial statements.
Kopin's 18,000,000 Series Seed-1 Preferred shares of LST and 18,000,000 common shares of LSA were repurchased for $1.00 each, dated June 10, 2026.
Technology License Agreement with LST was terminated April 10, 2026; the Services Agreement expired in 2025.
Kopin will pay LST a royalty of $7.50 per display on certain customer orders secured between April 10, 2026 and October 30, 2026.
Kopin issued a $25,000 NRE purchase order, payable within 30 days, and LST's limited license to fulfill existing firm orders runs through July 15, 2026.
Brady Corporation entered a $1.0 billion credit agreement on June 12, 2026, consisting of a $500 million term loan and a $500 million revolving credit facility, which replaced its prior 2019 credit agreement. The company says it will use the borrowings mainly to finance its pending acquisition of Honeywell's Productivity Solutions and Services business, which means the company will take on new debt tied to that deal.
Credit agreement dated June 12, 2026: $500 million term loan plus $500 million revolving credit facility, maturing June 12, 2031
Replaces previous credit agreement dated August 1, 2019; €13.0 million of revolving loans were exchanged and other obligations repaid in full
Revolver availability capped at $300 million until the PSS acquisition closes, then expands to the full $500 million
Maximum consolidated net leverage ratio of 3.50 to 1.00 (temporarily up to 4.00 to 1.00 after closing) and minimum interest coverage of 3.00 to 1.00
Pfizer said on June 18, 2026 that it is reaffirming all components of its full-year 2026 guidance, following its announcement of a Chief Financial Officer transition the same day. The guidance includes revenues of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, unchanged from the December 16, 2025 guidance and the May 5, 2026 reaffirmation.
Full-year 2026 revenue guidance reaffirmed at $59.5 billion to $62.5 billion
Adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00
Guidance first issued December 16, 2025 and reaffirmed May 5, 2026 on the first quarter earnings call
Filing follows a Chief Financial Officer transition announcement made June 18, 2026
HCA Healthcare said Dr. Michael Cuffe, Executive Vice President and Chief Clinical Officer, will step down from that role effective August 31, 2026, under an agreement reached June 15, 2026. He will then serve in a transitional role until February 2027. The filing does not name a successor, and the change involves a senior clinical executive rather than the chief executive or chief financial officer.
Dr. Michael Cuffe steps down as Executive Vice President and Chief Clinical Officer effective August 31, 2026
Transitional role with the company continues until February 2027
Eligible for benefits under the company's executive severance policy and applicable incentive plans
Agreement reached June 15, 2026; 8-K dated June 18, 2026
Broadcom said its cash tender offers for certain senior notes expired on June 17, 2026, and raised the aggregate purchase cap from $2.5 billion to $3.0 billion. About $5.5 billion of notes were tendered, and about $2.9 billion was accepted for purchase, all from the 4.926% notes due 2037 and the 4.900% notes due 2038.
Consideration cap raised from $2.5 billion to $3.0 billion, excluding accrued coupon payments.
About $5.5 billion of notes were validly tendered by the June 17, 2026 expiration; about $2.9 billion was accepted.
Accepted: $1,843,836,000 of 4.926% notes due 2037 at $982.01 per $1,000 principal, and $1,050,537,000 of 4.900% notes due 2038 at $970.29 per $1,000.
Initial settlement is expected June 18, 2026; guaranteed delivery settlement is expected June 23, 2026.
Otter Tail's subsidiaries Northern Pipe Products and Vinyltech agreed on June 17, 2026 to pay $30 million into a settlement fund to resolve end-user class claims in the PVC Pipe Antitrust Litigation. The settlement requires court approval, and the company says it will use available cash and does not expect a material adverse effect on its financial position or liquidity.
Settlement amount: $30 million, paid into a fund after preliminary court approval, with payment due about 21 days after that approval.
Settlement covers End-User Class claims in In re: PVC Pipe Antitrust Litigation (Case No. 1:24-cv-07639), U.S. District Court for the Northern District of Illinois.
The company does not admit wrongdoing and says it will keep defending itself if the settlement is not finalized.
The filing says the settlement is not expected to have a material adverse effect on financial position or liquidity.
Graham Corporation posted slides for its June 18, 2026 Investor Day, furnished as Exhibit 99.1 to this 8-K. The deck introduces new three-year targets for FY27 to FY29, including 8-10% incremental margin expansion, organic revenue growth toward top-quartile levels, and selective, accretive acquisitions, which give shareholders a stated framework for future performance.
Slides were posted June 18, 2026 and accompany the company's 2026 Investor Day presentation.
New targets cover FY27-FY29: 8-10% incremental margin expansion, organic revenue CAGR toward top quartile, and selective, accretive M&A.
The deck cites a 19% revenue CAGR since FY22 and a market capitalization of $1.3 billion as of the June 15, 2026 close.
The deck cites a Navy revenue opportunity of about $1.8 billion through 2056, based on strategic platform projections.
Chicago Atlantic Real Estate Finance (REFI) signed a merger agreement on June 17, 2026, under which it will elect to be regulated as a business development company and merge into Chicago Atlantic BDC (LIEN), with LIEN as the surviving public company. REFI stockholders would receive LIEN shares based on the ratio of each company's adjusted net asset value per share, and would be expected to own about 50.5% of the combined company based on March 31, 2026 figures, subject to the final ratio at closing.
Exchange is based on adjusted NAV per share at closing; REFI holders would be expected to own about 50.5% of LIEN based on March 31, 2026 NAVs.
REFI's current management agreement with its manager terminates automatically at the BDC election, without termination payment.
Closing is expected in the fourth quarter of 2026, subject to stockholder approvals at both companies and regulatory approvals.
Chicago Atlantic agreed to fund $2.0 million of REFI's transaction-related expenses at or immediately before closing.
Deluxe agreed on June 17, 2026 to acquire Celero Commerce, a payment processor for small to mid-sized businesses, for approximately $625 million in cash plus seller expenses and adjustments. The deal is funded with an incremental $375 million Term Loan A and drawings on Deluxe's existing revolving credit facility, and Deluxe expects net leverage of about 3.9x at closing. Deluxe reaffirmed its 2026 full-year guidance, which excludes Celero, and plans to update guidance after closing.
Purchase price of approximately $625 million in cash, funded by a $375 million incremental Term Loan A and the existing revolver
Deluxe expects net leverage of about 3.9x at closing and a return to below 3.0x within 24 months after closing
Celero reported over $200 million in 2025 revenue and a 28% adjusted EBITDA margin, per the company; Deluxe expects over $15 million in cost synergies by 2028
Closing is subject to regulatory approvals and customary conditions, with completion expected in the third quarter of 2026
Pfizer said Chief Financial Officer Dave Denton will leave the company on August 15, 2026 to take a consumer goods role outside the pharmaceutical industry. The company said the departure is not related to its financial or operating results. Cecile Guegan, a Pfizer finance executive since 2005, will serve as interim CFO from August 16 while Pfizer searches for a permanent successor.
Dave Denton notified Pfizer on June 16, 2026 that he will step down as CFO effective August 15, 2026
Cecile Guegan, Senior Vice President, Finance, Global Biopharmaceutical Business, becomes Interim CFO effective August 16, 2026
Pfizer is conducting a comprehensive internal and external search for a permanent successor
Chairman and CEO Albert Bourla credited Denton with leading transactions including Seagen, Biohaven and Metsera
Chicago Atlantic BDC (LIEN) signed a merger agreement under which REFI will elect to be regulated as a business development company and merge into LIEN in an all-stock deal, with LIEN continuing as the surviving public company. REFI stockholders would be expected to own about 50.5% of LIEN after closing, based on March 31, 2026 net asset values, and the final split depends on the NAV ratio calculated shortly before closing. Completion requires stockholder approvals at both companies, regulatory approvals and lender consents, with closing expected in the fourth quarter of 2026.
Former REFI stockholders would be expected to own approximately 50.5% of LIEN after the merger, based on March 31, 2026 NAVs; the final percentage depends on the closing NAV ratio.
Pro-forma NAV of $613 million and pro-forma portfolio of $771 million in investments, based on March 31, 2026 financial statements as reported on Form 10-Q.
LIEN board will consider in good faith a stock repurchase program of up to $25.0 million after closing, subject to market conditions.
Merger is currently expected to close in the fourth quarter of 2026; Chicago Atlantic has agreed to fund $2.0 million of REFI's transaction-related expenses.
Kroger reported first quarter 2026 results on June 18, 2026, with diluted EPS of $1.46, up from $1.29 a year earlier, and operating profit of $1,407 million, up from $1,322 million. The company reaffirmed its full-year 2026 guidance, including FIFO operating profit of $5.0 to $5.2 billion and EPS of $5.10 to $5.30, but identical sales without fuel grew only 1.0%, down from 3.2%.
Diluted EPS $1.46 vs. $1.29; adjusted EPS $1.58 vs. $1.49
Sales $46.1 billion vs. $45.1 billion; gross margin 22.7% vs. 23.0%
Identical sales without fuel rose 1.0% vs. 3.2% a year earlier
Full-year 2026 guidance reaffirmed; $2 billion share repurchase expected to be completed by end of fiscal 2026
Accenture reported third-quarter fiscal 2026 revenue of $18.72 billion, up 6% in U.S. dollars and 3% in local currency, and diluted EPS of $3.80, up 9%. It now expects full-year revenue growth of 3% to 4% in local currency, down from 3% to 5% in March, and raised the low end of its GAAP diluted EPS range to $13.38 to $13.50. Profit grew, but new bookings fell 2% and the revenue outlook was lowered.
Q3 FY26 revenue $18.72 billion, up 6% in U.S. dollars and 3% in local currency; diluted EPS $3.80 versus $3.49 a year earlier
Full-year FY26 local-currency revenue growth now 3% to 4%, versus 3% to 5% as of March 19, 2026
Full-year GAAP diluted EPS now $13.38 to $13.50, versus $13.25 to $13.50 previously
New bookings $19.32 billion, down 2% in U.S. dollars; free cash flow $3.6 billion; quarterly dividend of $1.63 per share payable August 14, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.